Omnicell has announced it has completed its acquisition of MTS Medication Technologies, according to a news release.
Omnicell is provider of medication and supply management solutions and analytics software for healthcare systems. MTS develops medication adherence packaging systems and serves 6,000 pharmacies worldwide.
"Providing medication management solutions across the entire spectrum of healthcare is aligned with the needs of our customers to increase efficiency by reducing recurrences of patient treatment needs," said Randall Lipps, chairman, president and CEO of Omnicell, in the release. "We believe that the addition of MTS to the existing Omnicell solutions uniquely positions Omnicell in the industry to supply the new demands for tracking and managing treatment beyond the acute care setting and use these capabilities to cut costs and improve outcomes."
MTS Medication Technologies will continue to operate under that brand, as a wholly-owned subsidiary of Omnicell, immediately following the closing of the acquisition.
Omnicell announced its plans to acquire MTS earlier this month.
Omnicell is headquartered in Mountain View, Calif., while MTS is based in North St. Petersburg, Fla.
Related Articles on Company Acquisitions:
AngioDynamics Acquires Navilyst Medical
Cardinal Health to Acquire Dik Drug
Ansell Completes Acquisition of Trelleborg Protective Products